The future of TRT, I hope?
Role of SARMs in Androgen Therapy for Men
Currently used androgenic formulations for replacement therapy are largely restricted to injectable or skin delivery formulations of testosterone or testosterone esters. Marketed injectable forms of testosterone esters (such as testosterone enanthate, propionate, or cypionate) produce undesirable fluctuations in testosterone blood levels, with supraphysiological concentrations early, and subnormal levels towards the end of the period before the next injection, providing an unsatisfactory profile and in some cases undesired side effects. Skin patches do provide a better blood level profile of testosterone, but skin irritation and daily application still limit the usefulness and acceptability of this form of therapy (1, 20, 21, 22). Oral preparations such as fluoxymesterone and 17-methyltestosterone are not currently used due to concerns about liver toxicity linked to the 17-alkyl group and because of somewhat lower efficacy. Thus, these compounds are considered obsolete (1, 20) and do not represent a viable form of therapy.
The discovery and development of SARMs provides the opportunity to design molecules that are not only orally active, but that target AR in different tissues to elicit the desired activity for each of the key indications benefiting from androgen therapy.